Patents
Literature
176 results about "Thioredoxin" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Thioredoxin is a class of small redox proteins known to be present in all organisms. It plays a role in many important biological processes, including redox signaling. In humans, thioredoxins are encoded by TXN and TXN2 genes. Loss-of-function mutation of either of the two human thioredoxin genes is lethal at the four-cell stage of the developing embryo. Although not entirely understood, thioredoxin plays a central role in humans and is increasingly linked to medicine through their response to reactive oxygen species (ROS). In plants, thioredoxins regulate a spectrum of critical functions, ranging from photosynthesis to growth, flowering and the development and germination of seeds. They have also recently been found to play a role in cell-to-cell communication.
Expression of heterologous proteins
An expression system which provides heterologous proteins expressed by a non-native host organism but which have native-protein-like biological activity and / or structure. Disclosed are vectors, expression hosts and methods for expressing the heterologous proteins. The expression system involves co-expression of protein factor(s) which is / are capable of catalyzing disulphide bond formation and desired heterologous protein(s). The expression system is presented using yeast cells as the preferred host, protein disulphide isomerase (PDI) and thioredoxin (TRX) as the preferred examples of the protein factors and HCV-E2715 envelope glycoprotein and human FIGF as the preferred examples of the heterologous proteins.
Owner:NOVARTIS AG
Histone Deacetylase Inhibitor Prodrugs
InactiveUS20090023786A1Increased aqueous solubilityImprove permeabilityBiocideNervous disorderAbnormal tissue growthHydroxamic acid
The present invention is directed to prodrugs of hydroxamic acid based histone deacetylase (HDAC) inhibitors, e.g., suberoylanilide hydroxamic acid (SAHA). The prodrugs are acylated derivatives having increased aqueous solubility and cellular permeability as compared with the free hydroxamic acid, and are useful for inhibiting HDACs, and for selectively inducing terminal differentiation, cell growth arrest and / or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the prodrugs of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The prodrugs of the invention are also useful in the prevention and treatment of thioredoxin (TRX)-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and / or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases.
Owner:MERCK HDAC RESEARCH LLC
Stabilized bioactive peptides and methods of identification, synthesis, and use
InactiveUS20060099571A1Slow down rate of intracellular degradationBacteriaPeptide/protein ingredientsLac operonΑ helical
An intracellular selection system allows screening for peptide bioactivity and stability. Randomized recombinant peptides are screened for bioactivity in a tightly regulated expression system, preferably derived from the wild-type lac operon. Bioactive peptides thus identified are inherently protease- and peptidase-resistant. Also provided are bioactive peptides stabilized by a stabilizing group at the N-terminus, the C-terminus, or both. The stabilizing group can be a small stable protein, such as the Rop protein, glutathione sulfotransferase, thioredoxin, maltose binding protein, or glutathione reductase, an α-helical moiety, or one or more proline residues.
Owner:PEPTIDE BIOSCI
Use of thioredoxin measurements for diagnostics and treatments
InactiveUS20050288227A1Increase doseLower Level RequirementsPeptide/protein ingredientsMicrobiological testing/measurementPeripheral blood mononuclear cellAutoimmune condition
The invention relates to methods for monitoring patient response to histone deacetylase inhibitors (e.g., suberoylanilide hydroxamic acid (SAHA)) or other therapeutic agents by measuring the level of thioredoxin in body fluids, tissues, and / or cells, such as peripheral blood mononuclear cells, plasma, or serum. The invention also relates to methods of monitoring and / or assisting with the diagnosis of a wide variety of thioredoxin-related diseases and conditions, such as inflammatory diseases, allergic diseases, autoimmune diseases, diseases associated with oxidative stress or diseases characterized by cellular hyperproliferation.
Owner:SLOAN KETTERING INST FOR CANCER RES
Vectors, cells and processes for pyrimidine deoxyribonucleosides production
Novel DNA constructs and host cells comprising the same are disclosed. DNA constructs comprise a transcription unit (e.g. operon) comprising DNA sequences encoding for ribonucleotide reductase and thioredoxin. In preferred embodiments, constructs further comprise DNA sequences encoding for thymidylate synthase and / or transcription units comprising sequences encoding for uridine kinase preferably together with dCTP deaminase. In particularly preferred embodiments, host cells comprising constructs having all of the above characteristics wherein the host cell displays repressed or no uracil DNA glycosylase activity. This may be achieved by removal of the host cell ung gene. Use of host cells in the manufacture of pyrimidine deoxyribonucleotides e.g. thymidine is also disclosed.
Owner:SMITHKLINE BECKMAN CORP
Method of expressing proteins with disulfide bridges
InactiveUS20060246541A1High affinityFacilitate the proper folding of nascent recombinant CN disintegrin domainBacteriaPeptide/protein ingredientsBiotechnologyADAMTS Proteins
This invention relates to methods of expressing eukaryotic proteins in prokaryotic hosts, particularly eukaryotic proteins that require formation of disulfide bridges for biological activity. Various approaches are used including fusion to thioredoxin, cytoplasmic expression of disulfide isomerases, deficiencies in thioredoxin and / or glutathione reductases, deficiencies in proteases, and the like. The method is applicable to express monomeric and dimeric forms of the eukaryotic protein with biological activity such as monomeric and dimeric forms of a disintegrin or a disintegrin domain. Included are the vectors, host cells expressing the proteins, the expressed proteins and methods of using the proteins.
Owner:UNIV OF SOUTHERN CALIFORNIA
Stabilized bioactive peptides and methods of identification, synthesis and use
Owner:PEPTIDE BIOSCI
Gene engineering bacterium, preparation and use thereof
InactiveCN101054569AHigh expressionOptimize purification stepsBacteriaEnzymesEscherichia coliBiotechnology
The present invention relates to a gene engineered bacteria, and its preparation method and uses, belongs to biological engineering field. The gene engineered bacteria is composed of plasmid and host bacteria in which host bacteria is any one of Ecoli DH5alpha,BL21(DE3) or Rosetta-gami(DE3), the recombinant plasmid is pET32a(+) containing gene GAD65. The construction method of engineered bacteria comprise: designing Nest-PCR upper-stream primer and down-stream primer, amplifying human GAD65 gene fragment using PCR from human pancreas cDNA library, transforming Ecoli via vector and obtaining highly effective expression recombinant human GAD65 gene engineered bacteria. The inventive engineered bacteria can be used to produce soluble active thioredoxin- human Glutamic Decarboxylase 65 fusion protein and active recombinant human GAD65 which has enzymatic activity and immunological activity and are easy to purify. The expression volume is high and cost is low .
Owner:EAST CHINA NORMAL UNIV
Stabilized bioactive peptides and methods of identification, synthesis, and use
InactiveUS7365162B2Slow down rate of intracellular degradationBacteriaPeptide/protein ingredientsLac operonWild type
An intracellular selection system allows screening for peptide bioactivity and stability. Randomized recombinant peptides are screened for bioactivity in a tightly regulated expression system, preferably derived from the wild-type lac operon. Bioactive peptides thus identified are inherently protease- and peptidase-resistant. Also provided are bioactive peptides stabilized by a stabilizing group at the N-terminus, the C-terminus, or both. The stabilizing group can be a small stable protein, such as the Rop protein, glutathione sulfotransferase, thioredoxin, maltose binding protein, or glutathione reductase, an α-helical moiety, or one or more proline residues.
Owner:PEPTIDE BIOSCI
Method of preselection patients for anti-VEGF, anti-HIF-1 or anti-thioredoxin therapy
InactiveUS20060104902A1Decreased patient survivalImprove the level ofCompounds screening/testingBiocideBlood capillaryNormal blood volume
The present invention generally relates to methods of preselecting patients for treatment with an anti-VEGF therapy, anti-HIF-1 therapy or anti-thioredoxin therapy. Aspects of the invention combine methods of dynamic contrast enhanced-MRI and diffusion weighted-MRI for the detection of tumor histology. The methodology disclosed herein detects tissue blood volume, tumor vascularity, and abnormal capillary permeability, thereby determining tumor vascularity to determine whether a patient should be administered such therapy.
Owner:PROLX PHARMA +1
Non-inducing expressing gene engineering strain and structural process and application thereof
The invention discloses a non-induced expression genetic engineering strain and the constructing method and the application. The host cell of the strain is enteric bacilli E.coliBL21, CCTCC M205136, PCR expanding hrp Z gene section to clone to pGEM-T carrier, ferment cutting and bonding by EcoR I / Xho I, inserting the hrp Z gene into the enteric bacilli expression carrier pET-32b(+) lower reaches of thioredoxin, constructing rebuilding expression particle pET-32b-hrp, and transferring into E.coliBL21, filtering to gain positive clone. The non-induced expression rebuilt albumen HrpZ, SDS-PAGE shows that high efficiently expresses APDZ albumen. The rebuilt albumen has good prevention effect to plant disease and could improves the yield.
Owner:WUHAN UNIV
Nucleic acid structure and expression carrier for enhancing recombinant protein production and mass-production of recombinant protein
InactiveCN1712534AImprove propertiesProtection from decompositionHaemoglobins/myoglobinsAntibody mimetics/scaffoldsNucleic acid structureGene product
Nucleic acid construction and expression carrier for improving recombinant protein production and production of recombinant protein are disclosed. The process is carried out by cloning first nucleic acid sequence of coded thioredoxin and second nucleic acid sequence of coded ferrohemoglobin into recombinant host cell, reinforcing the recombinant host cell production and helping to release intracellular stress.
Owner:FENG CHIA UNIVERSITY
Application of protein and proteome in preparation of liver cirrhosis diagnostic reagent
InactiveCN102183661AHigh sensitivityBiological testingPIGMENT EPITHELIUM-DERIVED FACTORProtein markers
The invention relates to application of protein and proteome in preparation of a liver cirrhosis diagnostic reagent. The protein comprises Lumican, Tetranectin, Pro-platelet basic protein (PBP), Pigment epithelium-derived factor (PEDF), Insulin-like growth factor binding protein 3 (IGFbp-3), Sex hormone-binding globulin (SHBG), Thioredoxin and composition of parts in the liver cirrhosis diagnostic reagent. Multiple proteins related with health and disease states are identified and evaluated in large range by adopting a proteome technology, the screened biomarkers for identifying hepatitis and liver fibrosis are used for predicting the degree of hepatitis and liver fibrosis and can be used for preparing a kit for diagnosing liver cirrhosis and liver cirrhosis level, and the protein markers identify the sensitivity of liver cirrhosis and degree thereof; and by combining the optimal conditions of various protein markers, the sensitivity can reach 89 percent, the specificity reaches over 90 percent, and the sensitivity and the specificity are higher than those of any known detection method.
Owner:天津宝瑞生物技术有限公司
Recombination fusion protein Trx-TAT-hMsrA and application thereof to aspect of nerve cell protection
InactiveCN101974089AOvercome the disadvantage of not being able to enter the cellResist damageNervous disorderPeptide/protein ingredientsCell membraneThioredoxin
The invention discloses a preparation method of a fusion protein Trx-TAT-hMsrA and application thereof to an aspect of nerve cell protection. The fusion protein Trx-TAT-hMsrA comprises a TAT protein transduction structure domain, thioredoxin Trx and anthropogenic methionine sulfoxide reductase hMsrA. The fusion protein of the invention has various biological effects for reducing the oxidization of functional protein methionine residues, treating oxidative stress injury, relieving the relevant nerve cell pathological change of parkinsonism, preventing and treating calcium ion overloading and the like, simultaneously has good capability for entering nerve cells through the epicyte, and belongs to novel biotechnological medicine candidates with good druggability.
Owner:HUAZHONG UNIV OF SCI & TECH
Methods for production of proteins
InactiveUS7223566B2Accurate size determinationHigh color intensityFungiBacteriaEscherichia coliPresent method
Owner:LIFE TECH CORP
Cyanea capillata thioredoxin and coding gene and application thereof
ActiveCN103232979AStrong antioxidant activityEasy to prepareCosmetic preparationsPeptide/protein ingredientsAgricultural scienceNucleotide
The invention belongs to the technical field of biomedicine and provides a cyanea capillata thioredoxin. Currently, researches and reports related to jellyfish thioredoxin are not seen yet. The cyanea capillata thioredoxin provided by the invention has protein formed by an amino acid sequence shown in SEQ ID NO: 2. The invention further provides a coding gene of the cyanea capillata thioredoxin, wherein the coding gene has a nucleotide sequence shown in SEQ ID NO: 1. Meanwhile, the invention further provides application of the cyanea capillata thioredoxin and the coding gene of the cyanea capillata thioredoxin in preparation of anti-oxidation drugs, anti-radiation drugs, skin protectants, food preservatives, anti-aging drugs and the like. The cyanea capillata thioredoxin and the coding gene of the cyanea capillata thioredoxin have greater clinical application values.
Owner:SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
Staphylococcus aureus fusion protein of fibronectin and bindin, its preparation method and uses
InactiveCN1884302AImprove protectionImproving immunogenicityAntibacterial agentsSkeletal disorderStaphylococcus cohniiMicrococcus pyogenes
The invention discloses a fusion protein for Micrococcus pyogenes surface protein, and also discloses the method for preparing the same as well as its usage. The fusion protein is fused by Micrococcus pyogenes fnb and thioredoxin Trx on expression carrier, and the process comprises preparation of Micrococcus pyogenes surface protein fnb coding gene, colony of fnb coding gene into expression carrier and protein fusion. The fusion protein is soluble protein and retains immunity of natural protein. It is detected that said fusion protein is characterized by good response for humoral immunity and cell immunity, enlargement of protection range of protein vaccine and prevention of infection caused by most of Micrococcus pyogenes.
Owner:MICROBE EPIDEMIC DISEASE INST OF PLA MILITARY MEDICAL ACAD OF SCI
Nucleic acid construct and expression vector for enhancing the production of recombinant protein, and method for the massive production of recombinant protein
InactiveUS20050287669A1High protein yieldResist protein toxicityFungiBacteriaGene productNucleic acid sequencing
Disclosed herein are nucleic acid constructs and expression vectors for enhancing the production of recombinant polypeptides / proteins, and methods for the massive production of recombinant polypeptides / proteins, in which a first nucleic acid sequence encoding thioredoxin and a second nucleic acid sequence encoding hemoglobin are cloned into a host cell, thereby enhancing the capability of the thus formed recombinant host cell in producing a selected gene product, and thereby assisting said recombinant host cell in relieving intracellular stress due to the overproduction of said gene product.
Owner:FENG CHIA UNIVERSITY +1
Information acquisition apparatus on concentration of thioredoxins in sample, stress level information acquisition apparatus and stress level judging method
InactiveUS20070190590A1Reduced form requirementsMicrobiological testing/measurementAnalogue computers for chemical processesConcentration ratioStress level
The invention is to provide an information acquisition apparatus for acquiring information relating to at least one of an oxidized form concentration, a reduced form concentration and a ratio of the concentrations of thioredoxin, useful for judging a stress level, and a stress level information acquisition apparatus and a stress level judging method utilizing the same. A reaction by an enzyme or the like catalyzing an redox reaction of thioredoxins is used to measure at least one of an oxidized form concentration, a reduced form concentration and a concentration ratio of thioredoxins, and data of such measurement is used for judging the stress level of a subject person.
Owner:CANON KK
Process for producing recombinant insulin-like growth factor-1(IGF-1) amalgamation protein
InactiveCN101429519AEasy to placePromote formationBacteriaMicroorganism based processesBiotechnologyHydroxylamine
The invention discloses a method for preparing recombined human insulin growth factor-1(IGF-1) fused protein, which belongs to the field of biological medicine field in biological technique. The invention adopts the genetic engineering fungus fermentation method for production: a. designing and synthesizing recombining human IGF-1 fused protein gene; b. constructing an expression vector of the recombined human IGF-1 fused protein; c. utilizing the expression vector to convert the host to construct the genetic engineering fungus; and d. utilizing the genetic engineering fungus to ferment the recombined human IGF-1 fused protein. In the method, according to the characteristics that the first amino acid of the natural IGF-1 is glycine(GLy, G), a leading peptide is added before the natural IGF-1, and a hydroxylamine specific cracking part(Asn-Gly peptide bond) is designed between the leading peptide and the natural IGF-1, thereby making the expression products stable and lowering purification cost. In the method, the fused protein in serial expression is used, wherein the N end is thioredoxin, and the C end is IGF-1, so that the expression products are more stable, and the separation method is simple and cheap. The method has wide application prospect.
Owner:FUJIAN MEDICAL UNIV
Histone deacetylase inhibitor prodrugs
InactiveUS8227636B2Good cell permeabilityPrevent proliferationBiocideNervous disorderAbnormal tissue growthHydroxamic acid
The present invention is directed to prodrugs of hydroxamic acid based histone deacetylase (HDAC) inhibitors, e.g., suberoylanilide hydroxamic acid (SAHA). The prodrugs are acylated derivatives having increased aqueous solubility and cellular permeability as compared with the free hydroxamic acid, and are useful for inhibiting HDACs, and for selectively inducing terminal differentiation, cell growth arrest and / or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the prodrugs of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The prodrugs of the invention are also useful in the prevention and treatment of thioredoxin (TRX)-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and / or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases.
Owner:MERCK HDAC RESEARCH LLC
Methods for production of proteins
InactiveUS20060286633A1Rapid isolationFast purificationFungiBacteriaEscherichia coliInclusion bodies
The current invention provides methods for producing a polypeptide as inclusion bodies in bacterial host cells. The present methods are carried out by forming a gene construct comprising the genetic sequence encoding a polypeptide operatively linked to that of an inclusion partner protein, such as E. coli thioredoxin or a modified E. coli thioredoxin, such that host cells comprising the gene construct produce the polypeptide as intracellular inclusion bodies. The methods of the present invention facilitate the rapid isolation and purification of recombinant proteins. In addition, the present methods may be useful for producing polypeptides or proteins which are small and are typically difficult to express, as well as those proteins that are toxic to host cells such as E. coli. The present invention also provides plasmids, vectors and host cells to be used in the present invention for production of polypeptides, and methods of production of polypeptides using these vectors and host cells. The invention further provides methods for producing protein molecular weight ladders for use in protein gel electrophoresis, as well as proteins and protein molecular weight ladders produced by these methods.
Owner:LIFE TECH CORP
Method for preparing human parathyroid hormone 1-34
InactiveCN102304518APromotes high-yield extracellular accumulationAvoid attackPeptide preparation methodsParathyroid hormonesProtein targetThioredoxin
The invention relates to the technical field of biomedical engineering, and relates to a method for preparing human parathyroid hormone (1-34) through fermenting and purifying human parathyroid hormone 1-34 recombinant engineering bacteria constructed by a gene engineering method. The method provided by the invention comprises the following steps: fusing and expressing the genes for coding human parathyroid hormone and a thioredoxin label, and further constructing and finishing genetic engineering bacteria capable of highly expressing human parathyroid hormone; adding IPTG (isopropyl beta D thiogalactopy ranoside) and triton X-100 in the fermentation process by adopting a chemosmosis fermentation technology so as to improve the release of proteins extracellularly in the fermentation process, which is good for the continuous synthesis of proteins, and avoiding the attack of endoproteinase, thus protein high-yield extracellular accumulation is promoted; and simultaneously carrying out heat treatment on a fermentation liquid when the fermentation reaches the final point aiming at the heat stability of thioredoxin fusion, thus initially purified target proteins are directly recycled and obtained from a fermentation liquor supernatant after centrifugation.
Owner:中国科学院上海生命科学研究院湖州工业生物技术中心
Preparation and use of swine foot-and-mouth disease recombinant immune composite peptide
InactiveCN101376887AImproving immunogenicityGood immune effectBacteriaMicroorganism based processesEscherichia coliAdjuvant
The invention relates to a method for constructing porcine fmd recombinant immune complex peptide and an application thereof, which belongs to the technical field of biological engineering. The immune multi-peptide adjuvant is fused with aphthovirus novel auxiliary T cell epiposition (I-S-I-S-E-I-K-G-V-I-V-H-K-I-E-T-I-L-F) and Bursin mimic peptide (T-P-N-L-K-H-G) by a flexible Linker. A fusion gene is inserted into an expression carrier to be converted into colon bacillus, gene engineering strains which express the porcine fmd recombinant immune complex peptide with high efficiency are obtained, and the fusion protein of the porcine fmd recombinant immune complex peptide is obtained after liquid culture and purification; the thioredoxin in the fusion protein is removed by enterokinase with His label on the N end, and the single porcine fmd recombinant immune complex peptide can be obtained after affinity chromatography purification with very high sample purity. The recombinant immune complex peptide can serve as the novel immune multi-peptide adjuvant of the foot-and-mouth disease vaccine. Animal immune experiments prove that the method has high safety but no toxicity and side effect, and can effectively enhance the immunity of organisms and cells and the immunity level of body fluid.
Owner:NANJING AGRICULTURAL UNIVERSITY
Method for preparing parathormone 1-34
This invention provides a method for preparing recombinant human parathyroid hormone 1-34 (rhPTH (1-34)). The method comprised: (1) expressing with an expression vector capable of expressing a fusion protein with an amino acid sequence (from N-terminal to C-terminal) containing thioredoxin, (His) 6, enterokinase recognition site and parathyroid hormone 1-34 peptide; (2) purifying the fusion protein by nickel ion complexation affinity chromatography; (3) cutting the purified fusion protein with enterokinase to release the rhPTH (1-34) from the fusion protein. By this method, rhPTH (1-34) can be purified rapidly, simply and efficiently, and the recovery yield is largely increased.
Owner:DONGGUAN TAILI BIOTECH
TrxA and SUMO double-solubilized expression tag sequence and application thereof
InactiveCN108300728APromotes proper foldingHigh expressionNucleic acid vectorVector-based foreign material introductionSolubilityForeign protein
The invention relates to the fields of gene recombination and prokaryotic expression of proteins, and concretely relates to a double-solubilized expression tag sequence formed through fusing Escherichia coli thioredoxin TrxA and a small ubiquitin-like modifier SUMO, and an application thereof in a prokaryotic expression vector. An SUMO and TrxA double-solubilized expression tag has a base sequencerepresented by SEQ ID NO:1 in a sequence table. The sequence is applied to the upstream of the foreign protein encoding gene of the prokaryotic expression vector, and participates in fusion expression as a solubilizing tag together with a foreign gene in order to significantly promote the solubility of the expressed foreign protein and improve the recovery efficiency of a soluble foreign protein.
Owner:SHENYANG INST OF APPLIED ECOLOGY - CHINESE ACAD OF SCI
Detection and quantitation of full-length thioredoxin (TRX) and truncated thioredoxin (TRX 80) in complex samples
The present invention relates, e.g., to a method for detecting a full-length protein and a truncated form (e.g., a naturally occurring cleavage product) thereof, in a sample, comprisingoptionally denaturing and reducing proteins in the sample,cleaving the proteins into smaller peptides, anddetecting a unique peptide identifier for the full-length protein and / or a unique peptide identifier for the truncated protein, in the sample.In one embodiment of the invention, the full-length protein is thioredoxin (TRX), and the truncated form thereof is its biologically active, C-terminal truncated, 10 kDa cleavage product, TRX 80.
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE
Expression of properly folded and soluble extracellular domain of a gonadotropin receptor
InactiveUS20020128190A1Reduce productionEasy to producePeptide/protein ingredientsAntibody mimetics/scaffoldsPregnancyGonadotropin receptor
This invention provides a nucleic acid which encodes a soluble polypeptide which comprises the extracellular domain of a gonadotropin receptor and thioredoxin, wherein the soluble polypeptide is capable of binding to the gonadotropin. This invention also provides the polypeptides encoded by these nucleic acids and methods to produce the polypeptides. This invention also provides methods of preventing or terminating pregnancy, preventing or treating cancer, and decreasing androgen and estrogen production.
Owner:THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK
Fusion protein containing haman parathyroxin 1-34 and its expression vector
ActiveCN1900120AAntibody mimetics/scaffoldsFusions for enhanced expression stability/foldingThioredoxinProteolytic enzymes
The present invention provides a kind of fusion protein, which possesses thioredoxin sequence and parathormone peptide 1-34 located in the downstream of the thioredoxin. Preferably, the fusion protein possesses also connecting peptide containing proteolytic enzyme recognizing site and located between the thioredoxin and the parathormone peptide 1-34. From the fusion protein, human parathormone peptide 1-34 may be prepared.
Owner:BEIJING GENETECH PHARML
Thioredoxin and preparation method and application thereof
InactiveCN102586202AEasy to makeApparent reductase activityAntinoxious agentsOxidoreductasesThiogalactosidesThioredoxin
The invention relates to the field of molecular biology, in particular to Cynoglossus semilaevis thioredoxin and a preparation method and application thereof. The thioredoxin is shown as an amino acid sequence in a sequence table SEQ ID No.1. The preparation method comprises the following steps of: constructing a plasmid pETrx, transforming the plasmid pETrx by using BL21(DE3) to obtain BL21(DE3) / pETrx, inducing by using isopropyl-beta-D-isopropylthiogalactoside, and purifying recombinant protein by using an affinity chromatography column to obtain the thioredoxin. The thioredoxin has remarkable reductase activity, a remarkable antioxidation effect and a remarkable cell growth promotion effect.
Owner:INST OF OCEANOLOGY - CHINESE ACAD OF SCI